Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

are include deemed dividends, preferred

stock accretion, and changes in the fair value of warrant liability.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with res
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- Intarcia Therapeutics, Inc. today announced the ... the cost and predictability of non-adherence in type 2 ... of the European Association for the Study of Diabetes ... , Ph.D., of Analysis Group, Inc. presented data from ... studies to characterize the prevalence of non-adherence and serial ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced that it has been granted a ... Office on its unique delivery system for delivering ... phagocytic cells for the treatment of diseases with ...
(Date:9/17/2014)... MESSENGER has just celebrated its 10 year anniversary in ... of its latch valves, V27200-818, operating onboard this spacecraft. ... the planet Mercury. It is only the second spacecraft ... vast amount of information and images of the planet. ... that also include permanent magnets to maintain the valve ...
(Date:9/16/2014)... that can harvest energy from jaw movements has been ... It is hoped that the device can generate electricity ... of small-scale implantable or wearable electronic devices, such as ... devices. , The first results of the device,s performance ... journal Smart Materials and Structures . , Jaw ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4'Smart material' chin strap harvests energy from chewing 2
... pioneer in scalable, high performance cell loading systems, ... with industry experts on the,challenges in developing cell-based ... to the industry and will be held by ... of the respected industry experts leading this live ...
... Issues and Recommendations, BETHLEHEM, Pa., Nov. ... Clinical Value Marketing, Infusion Systems Division and ... for B. Braun Medical,Inc. (B. Braun), a ... services,recently represented B. Braun at the Institute ...
... CITY, Nov. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, will announce ... Thursday, November 13, 2008 at 7:30 a.m.,The Company ... discuss these,results later that same day at 10:00 ...
Cached Biology Technology:MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 3
(Date:9/16/2014)... are responsible for practically all vital functions in ... forward signals, transport particular substances and control immune ... proteins do not function independently of each other, ... examine the protein networks, you find many similarities ... from TUM,s Chair of Plant Systems Biology. "Some ...
(Date:9/16/2014)... Fla. , Sept. 16, 2014  Cross ... identity management solutions, announced today the launch of ... to authenticate the identity of an individual using ... Android-based Verifier Sentry rapidly reads credential documents with ... ID by matching the biometric to a live ...
(Date:9/16/2014)... of wild foods, autumn harks a season of bounty. ... luring intrepid collectors to woodlands in search of elusive ... in the allure of the treasure hunt, and their ... existence. But are the mushrooms which you are eating ... diverse yet vastly underdocumented although some estimates range ...
Breaking Biology News(10 mins):Good networkers make prime targets 2Cross Match Launches New Identity Management Handheld Solution 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3
... by children with neurofibromatosis type 1 (NF1), a genetic ... in improved cognitive function, according to a study in ... Characteristics of NF1 (incidence 1:3,000) include skin disorders, problems ... the frequent occurrence of cognitive disabilities, such as visual-spatial ...
... LAFAYETTE, Ind. - According to a new study, ... snowmelt in the western United States than was ... new water management challenges for agriculture, ecosystems and ... professor of earth and atmospheric sciences, discovered that ...
... at Cold Spring Harbor Laboratory (CSHL) are part of ... of an enzyme in the brain can reduce telltale ... CSHL Professor Yi Zhong, Ph.D., whose lab studies genetic ... of transgenic fruit flies that was central in the ...
Cached Biology News:Statin does not appear helpful for children with learning disabilities caused by genetic disorder 2Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves 2Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves 3Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain 2
... The Cellomics KineticScan™ Reader is ... "Smart Solutions for Cell-based Screening". ... the ability to do both ... of physiological processes, dynamic distribution ...
... into cells permits studies of protein-protein interactions, ... and transcription factor-mediated gene regulation. The most ... a specific protein in a mammalian cell ... the cell. ProteoJuice Protein Transfection Reagent is ...
... PULSin is an innovative reagent for highly ... cytoplasm of living cells. Unlike DNA transfection, ... the amount and timing of exogenous proteins ... proteins can now be studied. Real ...
... with a thin silicon strain chamber to ... fluorescence microscopy. Biaxial strain that is experienced ... be simulated by mechanical stretching or compression ... our strain chamber. Strain can be applied ...
Biology Products: